| 72.81 0.11 (0.15%) | 08-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 85.85 | 1-year : | 100.28 |
| Resists | First : | 73.51 | Second : | 85.85 |
| Pivot price | 68.66  |
|||
| Supports | First : | 62.21 | Second : | 55.24 |
| MAs | MA(5) : | 72.29 |
MA(20) : | 66.36 |
| MA(100) : | 63.81 |
MA(250) : | 67.25 |
|
| MACD | MACD : | 3.1 |
Signal : | 2.4 |
| %K %D | K(14,3) : | 92.6  |
D(3) : | 93.7 |
| RSI | RSI(14): 67.8 |
|||
| 52-week | High : | 85.25 | Low : | 48.2 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ TARS ] has closed below upper band by 22.6%. Bollinger Bands are 40.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 73.17 - 73.44 | 73.44 - 73.66 |
| Low: | 71.03 - 71.37 | 71.37 - 71.65 |
| Close: | 72.29 - 72.82 | 72.82 - 73.25 |
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
Wed, 19 Aug 2026
Tarsus (NASDAQ: TARS) ex-officer plans sale of 53K shares - Stock Titan
Mon, 17 Aug 2026
Tarsus Pharmaceuticals (TARS) Shares Just Moved, What Is Behind The Attention? - Sahm
Sun, 16 Aug 2026
Why Tarsus Pharmaceuticals (TARS) Is Up 6.8% After Raising XDEMVY 2026 Sales Guidance - And What's Next - simplywall.st
Thu, 13 Aug 2026
Tarsus Pharmaceuticals (TARS) Stock Looks Reasonable On Sales While Earnings Stay Weak - Yahoo Finance
Sat, 08 Aug 2026
Tarsus Pharmaceuticals (TARS) Stock Can Revenue Momentum Outrun Rising Costs - simplywall.st
Thu, 06 Aug 2026
Tarsus to Raise About $125M, Selling Stock at $56 a Share - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 44 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 2.8 (%) |
| Held by Institutions | 106 (%) |
| Shares Short | 6,020 (K) |
| Shares Short P.Month | 5,890 (K) |
| EPS | -1.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.01 |
| Profit Margin | -7.7 % |
| Operating Margin | -11.5 % |
| Return on Assets (ttm) | -5.5 % |
| Return on Equity (ttm) | -13.7 % |
| Qtrly Rev. Growth | 69.4 % |
| Gross Profit (p.s.) | 11.42 |
| Sales Per Share | 13.81 |
| EBITDA (p.s.) | -1.06 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 74 (M) |
| Levered Free Cash Flow | 67 (M) |
| PE Ratio | -68.05 |
| PEG Ratio | 0 |
| Price to Book value | 9.08 |
| Price to Sales | 5.26 |
| Price to Cash Flow | 43.08 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|